Biogen Idec, Inc. First Quarter Earnings Sneak Peek
S&P 500 (NYSE:SPY) component Biogen Idec, Inc. (NASDAQ:BIIB) will unveil its latest earnings on Tuesday, May 1, 2012. Biogen Idec is a global biotechnology company that meets the rising needs of therapeutic care providers and recipients.
Biogen Idec, Inc. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average analyst estimate is for profit of $1.44 per share, a rise of 1.4% from the company’s actual earnings for the year-ago quarter. During the past three months, the average estimate has moved down from $1.47. Between one and three months ago, the average estimate was unchanged. It has since dropped over the last month. Analysts are projecting profit to rise by 4.8% compared to last year’s $6.12.
Past Earnings Performance: Last quarter, the company beat estimates by 4 cents, coming in at net income of $1.50 per share against an estimate of profit of. The company also topped expectations in the third quarter of the last fiscal year.
Investing Insights: What’s the Future of Microsoft’s Stock?
Wall St. Revenue Expectations: Analysts predict a rise of 9.2% in revenue from the year-earlier quarter to $1.31 billion.
Analyst Ratings: Analysts are optimistic about this stock, with 14 analysts rating it as a buy, none rating it as a sell and six rating it as a hold.
A Look Back: In the fourth quarter of the last fiscal year, profit rose 25% to $300.2 million ($1.23 a share) from $240.3 million (99 cents a share) the year earlier, exceeding analyst expectations. Revenue rose 8.8% to $1.33 billion from $1.22 billion.
On the top line, the company is looking to build on two-straight revenue increases with this earnings announcement. Revenue rose 11.4% in the third quarter of the last fiscal year before climbing again in the fourth quarter of the last fiscal year of the last fiscal year.
The company enters this earnings announcement with steady profits recently. Net income has risen year-over-year average of 24.2% for the last four quarters.
Stock Price Performance: Between January 30, 2012 and April 25, 2012, the stock price rose $12.71 (10.9%), from $116.58 to $129.29. The stock price saw one of its best stretches over the last year between June 16, 2011 and June 29, 2011, when shares rose for 10 straight days, increasing 16.5% (+$15.45) over that span. It saw one of its worst periods between May 20, 2011 and May 27, 2011 when shares fell for six straight days, dropping 4% (-$3.90) over that span.
(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)
Don’t Miss These Additional Hot Stories: